Back
Results - Announcements
Mangalam Drugs and Organics Ltd consolidated sales down 15.11% on year in Q2FY2026, net profit witnessed a sharp fall of 43.07%
12-Aug-2026, 08:06
Mangalam Drugs and Organics Ltd share price slipped 0.04% to Rs 27.0 after the company's net profit tumbled by 43.07% to Rs 7.64 crore, while revenue from operations reduced 15.11% to Rs 57.12 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, gaining 4.31%. It has marginally improved by 0.98% over last one week and advanced by 11.49% in last one month while the market capitalization of Mangalam Drugs and Organics Ltd has inched up 0.45% and 9.99% in the same period respectively. Profit before tax (PBT) of Mangalam Drugs and Organics Ltd stood at Rs 6.75 crore in Q2 FY26, plunging by 48.08% year-on-year, and crashing by 49.13% quarter-on-quarter. EBITDA came in at Rs 1 crore, nosediving by 116.84% YoY and tanking 114.01% sequentially. Total expenses plunged by 22.26% to Rs 60.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 33.59 crore, marginally falling by 5.41% YoY, while employee benefits expense was at Rs 8.91 crore, ticking higher by 4.95% YoY. For the TTM ended FY26, revenue from operations declined by 13.55% to Rs 317.58 crore, while net profit tanked by 174.09% to Rs 6.72 crore, compared to previous TTM. EBITDA jumped by 1826% to Rs 34.01 crore, and PBT collapsed by 143.27% to Rs 4.79 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 42.59 crore in FY26, as against Rs 3.91 crore in FY25. Mangalam Drugs and Organics Ltd nosedived by 65.03% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.04% during the same period.
Mangalam Drugs and Organics Ltd share price slipped 0.04% to Rs 27.0 after the company's net profit tumbled by 43.07% to Rs 7.64 crore, while revenue from operations reduced 15.11% to Rs 57.12 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, gaining 4.31%. It has marginally improved by 0.98% over last one week and advanced by 11.49% in last one month while the market capitalization of Mangalam Drugs and Organics Ltd has inched up 0.45% and 9.99% in the same period respectively. Profit before tax (PBT) of Mangalam Drugs and Organics Ltd stood at Rs 6.75 crore in Q2 FY26, plunging by 48.08% year-on-year, and crashing by 49.13% quarter-on-quarter. EBITDA came in at Rs 1 crore, nosediving by 116.84% YoY and tanking 114.01% sequentially. Total expenses plunged by 22.26% to Rs 60.3 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 33.59 crore, marginally falling by 5.41% YoY, while employee benefits expense was at Rs 8.91 crore, ticking higher by 4.95% YoY. For the TTM ended FY26, revenue from operations declined by 13.55% to Rs 317.58 crore, while net profit tanked by 174.09% to Rs 6.72 crore, compared to previous TTM. EBITDA jumped by 1826% to Rs 34.01 crore, and PBT collapsed by 143.27% to Rs 4.79 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 42.59 crore in FY26, as against Rs 3.91 crore in FY25. Mangalam Drugs and Organics Ltd nosedived by 65.03% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.04% during the same period.